[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bleeding-in-the-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bleeding-in-the-brain":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100583572","phase-3-thrombolysis-in-factor-xa-inhibitors-trial-100583572",false,"NCT06878066","Thrombolysis in Factor Xa-inhibitors Trial","The Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With Recent Ingestion of Factor Xa-inhibitors Trial (SIFT)","SIFT","Inclusion Criteria:\n\n1. Participant must be 18 years of age or older.\n2. Ingestion of FXa inhibitors within the last 48 hours of symptom onset (or ongoing prescription of FXa inhibitor if unknown)\n3. Clinical diagnosis of AIS with disabling neurological deficit\n4. Presenting within 4.5 h of symptom onset or after awakening with symptoms of AIS with FLAIR-DWI mismatch on MRI as judged by the (neuro-) radiologist.\n5. Informed consent\n\nExclusion Criteria:\n\n1. Endovascular treatment eligible patients with isolated large vessel occlusion of the intracranial internal carotid artery (ICA), the M1 segment of the middle cerebral artery (MCA), or both confirmed by CT or MR angiography and expected time from randomization to groin puncture of \\\u003C30 minutes.\n2. Systolic BP \\>185 mmHg or diastolic BP \\>110 mmHg despite antihypertensive treatment.\n3. Known bleeding diathesis; manifest or recent severe bleeding; significant bleeding disorder last 6 months.\n4. Arterial puncture at a non-compressible site; biopsy or lumbar puncture \\\u003C7 days; major surgery, traumatic external heart massage, obstetrical delivery or serious trauma \\\u003C14 days; history of intracranial haemorrhage; stroke \\\u003C2 months, CNS neurosurgery \\\u003C2 months; serious head trauma \\\u003C2 months; pericarditis; sepsis; bacterial endocarditis; pericarditis; acute pancreatitis; neoplasm with increased bleeding risk; any serious medical illness likely to interact with treatment (i.e. aortic dissection); confounding pre-existent neurological or psychiatric disease.\n5. Any condition that, in the opinion of the treating physician, puts a patient at risk if treated with thrombolysis (i.e. signs of cerebral hemorrhage, known cerebral amyloid angiopathy, CT with signs of early ischemia greater than one-third of the middle cerebral artery territory).\n\n   Prior\u002FConcomitant Therapy\n6. Use of a) direct thrombin (II) inhibitor (Dabigatran) or b) warfarin with an INR ≥1.8; c) heparin \\\u003C48 h; d) treatment dose of LMWH \\\u003C24 h.\n\n   Prior\u002FConcurrent Clinical Study Experience\n7. Hypersensitivity to Alteplase or Tenecteplase","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours. This is because doctors worry that IVT might cause dangerous bleeding in the brain.\n\nHowever, new research suggests that IVT might be safe for these patients. Some studies even show that stroke patients on FXa inhibitors who receive IVT do not have a higher risk of brain bleeding than other stroke patients. But because these studies were not designed as full medical trials, doctors still avoid IVT for this group.\n\nThe SIFT trial will compare two groups of stroke patients who take FXa inhibitors:\n\nOne group will receive IVT to see if it helps them recover better. One group will not receive IVT, which is the current standard. Doctors will check if IVT helps with recovery and if it causes any serious bleeding. If IVT is found to be safe and effective, this study could change stroke treatment guidelines and help more patients get life-saving care.\n\nRight now, some guidelines say that stroke patients on FXa inhibitors should have a blood test before getting IVT, to measure how much of the drug is in their system. But these tests are not available in most hospitals, and waiting for results could delay important treatment. The SIFT trial will not require this test before giving IVT.\n\nMore and more people use FXa inhibitors to prevent strokes, but right now, they are being denied IVT based on old rules. If this study proves that IVT is safe for them, it could help doctors give better care to thousands of stroke patients.",[27,28,29,30,31,32,33,34,35],"Stroke","Stroke (in Patients With Atrial Fibrillation)","Ischemic Stroke","Acute Ischemic Stroke","Anticoagulant Therapy","Factor Xa Inhibitor","Intracranial Hemorrhages","Hemorrhagic Transformation Due to Acute Stroke","Bleeding in the Brain",[37,30,29,38,39,40,41,42,43,44,45,27,46,47,48],"Thrombolysis","Factor Xa Inhibitors","Atrial Fibrillation-Related Stroke","Intravenous Thrombolysis","Tissue Plasminogen Activator","Tenecteplase","Alteplase","Symptomatic Intracranial Hemorrhage","SIFT Trial","Acute stroke","Direct Oral Anticoagulants","DOACs","RECRUITING","2025-08-29",{"date":52,"type":53},"2025-09-02","ACTUAL",{"date":55,"type":53},"2025-03-14",{"date":57,"type":21},"2037-12-31",{"name":59,"class":60},"Guri Hagberg","OTHER",13]